DOCSLIB.ORG

Lergy, Bronchodilator, and Antiasthmatic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lergy, Bronchodilator, and Antiasthmatic Food and Drug Administration, HHS § 341.3 age and over: Oral dosage is 100 to 200 tions in this part and each of the gen- milligrams not more often than every 3 eral conditions established in § 330.1. to 4 hours. (b) References in this part to regu- latory sections of the Code of Federal PART 341—COLD, COUGH, AL- Regulations are to chapter I of title 21 LERGY, BRONCHODILATOR, AND unless otherwise noted. ANTIASTHMATIC DRUG PROD- [51 FR 35339, Oct. 2, 1986] UCTS FOR OVER-THE-COUNTER HUMAN USE § 341.3 Definitions. As used in this part: Subpart A—General Provisions (a) Bronchodilator drug. A drug used to overcome spasms that cause nar- Sec. rowing of the bronchial air tubes, such 341.1 Scope. 341.3 Definitions. as in the symptomatic treatment of the wheezing and shortness of breath of Subpart B—Active Ingredients asthma. (b) Oral antitussive drug. A drug that 341.12 Antihistamine active ingredients. either is taken by mouth or is dis- 341.14 Antitussive active ingredients. solved in the mouth in the form of a 341.16 Bronchodilator active ingredients. 341.18 Expectorant active ingredient. lozenge and acts systemically to re- 341.20 Nasal decongestant active ingredi- lieve cough. ents. (c) Topical antitussive drug. A drug 341.40 Permitted combinations of active in- that relieves cough when inhaled after gredients. being applied topically to the throat or chest in the form of an ointment or Subpart C—Labeling from a steam vaporizer, or when dis- 341.70 Labeling of OTC drug products con- solved in the mouth in the form of a taining ingredients that are used for lozenge for a local effect. treating concurrent symptoms (in either (d) Expectorant drug. A drug taken a single-ingredient or combination drug orally to promote or facilitate the re- product). moval of secretions from the res- 341.72 Labeling of antihistamine drug prod- piratory airways. ucts. (e) Antihistamine drug. A drug used 341.74 Labeling of antitussive drug prod- ucts. for the relief of the symptoms of hay 341.76 Labeling of bronchodilator drug prod- fever and upper respiratory allergies ucts. (allergic rhinitis). 341.78 Labeling of expectorant drug prod- (f) Oral nasal decongestant drug. A ucts. drug that is taken by mouth and acts 341.80 Labeling of nasal decongestant drug systemically to reduce nasal conges- products. tion caused by acute or chronic rhi- 341.85 Labeling of permitted combinations nitis. of active ingredients. 341.90 Professional labeling. (g) Topical nasal decongestant drug. A drug that when applied topically inside AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, the nose, in the form of drops, jellies, 360, 371. or sprays, or when inhaled intranasally EDITORIAL NOTE: Nomenclature changes to reduces nasal congestion caused by part 341 appear at 69 FR 13717, Mar. 24, 2004. acute or chronic rhinitis. (h) Calibrated dropper. A dropper cali- Subpart A—General Provisions brated such that the volume error in- curred in measuring any liquid does § 341.1 Scope. not exceed 15 percent under normal use (a) An over-the-counter cold, cough, conditions. allergy, bronchodilator, or anti- (i) Effervescent dosage form. A dosage asthmatic drug product in a form suit- form intended to be dissolved in water able for oral, inhalant, or topical ad- before administration. It contains, in ministration is generally recognized as addition to the active ingredient(s), safe and effective and is not mis- mixtures of acids (citric acid, tartaric branded if it meets each of the condi- acid) and sodium bicarbonate, which 243 VerDate Mar<15>2010 14:51 May 15, 2012 Jkt 226071 PO 00000 Frm 00253 Fmt 8010 Sfmt 8010 Y:\SGML\226071.XXX 226071 emcdonald on DSK7TPTVN1PROD with CFR § 341.12 21 CFR Ch. I (4–1–12 Edition) release carbon dioxide when dissolved § 341.16 Bronchodilator active ingredi- in water. ents. [51 FR 35339, Oct. 2, 1986, as amended at 54 FR The active ingredients of the product 8509, Feb. 28, 1989; 55 FR 40382, Oct. 3, 1990; 57 consist of any of the following when FR 58374, Dec. 9, 1992; 59 FR 43409, Aug. 23, used within the dosage limits estab- 1994; 71 FR 43362, Aug. 1, 2006] lished for each ingredient: (a) Ephedrine. Subpart B—Active Ingredients (b) Ephedrine hydrochloride. (c) Ephedrine sulfate. § 341.12 Antihistamine active ingredi- (d) Epinephrine. ents. (e) Epinephrine bitartrate. The active ingredient of the product (f) Racephedrine hydrochloride. (g) Racepinephrine hydrochloride. consists of any of the following when used within the dosage limits estab- [51 FR 35339, Oct. 2, 1986] lished for each ingredient: (a) Brompheniramine maleate. § 341.18 Expectorant active ingredient. (b) Chlorcyclizine hydrochloride. The active ingredient of the product (c) Chlorpheniramine maleate. is guaifenesin when used within the (d) Dexbrompheniramine maleate. dosage limits established in § 341.78(d). (e) Dexchlorpheniramine maleate. [54 FR 8509, Feb. 28, 1989] (f) Diphenhydramine citrate. (g) Diphenhydramine hydrochloride. § 341.20 Nasal decongestant active in- gredients. (h) Doxylamine succinate. (i) Phenindamine tartrate. The active ingredient of the product (j) Pheniramine maleate. consists of any of the following when (k) Pyrilamine maleate. used within the dosage limits and in the dosage forms established for each (l) Thonzylamine hydrochloride. ingredient: (m) Triprolidine hydrochloride. (a) Oral nasal decongestants. (1) Phen- [57 FR 58374, Dec. 9, 1992, as amended at 59 ylephrine hydrochloride. FR 4218, Jan. 28, 1994] (2) Pseudoephedrine hydrochloride. (3) Pseudoephedrine sulfate. § 341.14 Antitussive active ingredients. (4) Phenylephrine bitartrate in an ef- The active ingredients of the product fervescent dosage form. consist of any of the following when (b) Topical nasal decongestants. (1) used within the dosage limits and in Levmetamfetamine. the dosage forms established for each (2) Ephedrine. (3) Ephedrine hydrochloride. ingredient in § 341.74(d): (4) Ephedrine sulfate. (a) Oral antitussives. (1) Chlophedianol (5) [Reserved] hydrochloride. (6) Naphazoline hydrochloride. (2) Codeine ingredients. The following (7) Oxymetazoline hydrochloride. ingredients may be used only in com- (8) Phenylephrine hydrochloride. bination in accordance with § 290.2 and (9) Propylhexedrine. 21 CFR 1308.15(c). (10) Xylometazoline hydrochloride. (i) Codeine. (ii) Codeine phosphate. [59 FR 43409, Aug. 23, 1994, as amended at 63 FR 40650, July 30, 1998; 71 FR 43362, Aug. 1, (iii) Codeine sulfate. 2006] (3) Dextromethorphan. (4) Dextromethorphan hydrobromide. § 341.40 Permitted combinations of ac- (5) Diphenhydramine citrate. tive ingredients. (6) Diphenhydramine hydrochloride. The following combinations are per- (b) Topical antitussives. (1) Camphor. mitted provided each active ingredient (2) Menthol. is present within the dosage limits es- tablished in parts 341, 343, and 356 of [52 FR 30055, Aug. 12, 1987, as amended at 59 this chapter and the product is labeled FR 29174, June 3, 1994; 67 FR 4907, Feb. 1, 2002] in accordance with §§ 341.70 or 341.85: 244 VerDate Mar<15>2010 14:51 May 15, 2012 Jkt 226071 PO 00000 Frm 00254 Fmt 8010 Sfmt 8010 Y:\SGML\226071.XXX 226071 emcdonald on DSK7TPTVN1PROD with CFR.
Load more

Recommended publications
  • Pharmacotherapeutic Considerations for Individuals with Down Syndrome Erik Hefti
    Harrisburg University of Science and Technology Digital Commons at Harrisburg University Harrisburg University Faculty Works 12-8-2016 Pharmacotherapeutic Considerations for Individuals with Down Syndrome Erik Hefti Follow this and additional works at: http://digitalcommons.harrisburgu.edu/faculty-works Part of the Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, and the Medicinal and Pharmaceutical Chemistry Commons R EVIEW O F T HERAPEUTICS Pharmacotherapeutic Considerations for Individuals with Down Syndrome Erik Hefti,* and Javier G. Blanco* Department of Pharmaceutical Sciences, The School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, New York Down syndrome (DS; trisomy 21) is the most common survivable disorder due to aneuploidy. Individ- uals with DS may experience multiple comorbid health problems including congenital heart defects, endocrine abnormalities, skin and dental problems, seizure disorders, leukemia, dementia, and obesity. These associated conditions may necessitate pharmacotherapeutic management with various drugs. The complex pathobiology of DS may alter drug disposition and drug response in some individuals. For example, reports have documented increased rates of adverse drug reactions in patients with DS treated for leukemia and dementia. Intellectual disability resulting from DS may impact adherence to medication regimens. In this review, we highlight literature focused on pharmacotherapy for individu- als with DS. We discuss reports of altered drug disposition or response in patients with DS and explore social factors that may impact medication adherence in the DS setting. Enhanced monitoring during drug therapy in individuals with DS is justified based on reports of altered drug disposition, drug response, and other characteristics present in this population.
    [Show full text]
  • I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and Therapeutics, Seoul St
    2014;22(1):13-18 TCP Translational and Clinical Pharmacology http://dx.doi.org/10.12793/tcp.2014.22.1.13 Clinical Pharmacology Review for Primary Health Care Providers: I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and Therapeutics, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 137-701, Korea *Correspondence: S. Han; Tel: +82-2-2258-7326, Fax: +82-2-2258-7876, E-mail: [email protected] Received 31 May 2014 Primary health care providers play a critical role in maintaining public health, and the appropri- Accepted 31 May 2014 ate use of pharmaceutical products is one of the major parts of their practice. This series of articles, pISSN: 2289-0882 entitled ‘Clinical Pharmacology Review for Primary Health Care Providers,’ is intended to help pri- mary health care providers select more appropriate prescriptions for frequently used drugs based on up-to-date information. We expect that this effort will contribute to improvements in public health and diminish unnecessary drug use. Introduction tion on the H1 receptor.[8] THERAPEU Antihistamines include some of the most frequently prescribed drugs in the primary health care environment for the symp- Generations and Classes tomatic relief of allergic diseases, the common cold, urticaria, Many primary health care providers are well-informed about T and insomnia.[1-5] The importance of antihistamines has been the different ‘generations’ of antihistamines but not about the ICS TU emphasized as the prevalence of target diseases increases.[6,7] different ‘classes’ characterized according to chemical structure. However, the appropriate use, clinical effectiveness, and target [1] This discrepancy seems reasonable because ‘inter-generation’ T populations for prescription of antihistamines are still a matter differences are more prominent than ‘inter-class’ differences.
    [Show full text]
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • FDA Warns That Abuse and Misuse of the Nasal Decongestant Propylhexedrine Causes Serious Harm This Includes Heart and Mental Health Problems Or Death
    FDA warns that abuse and misuse of the nasal decongestant propylhexedrine causes serious harm This includes heart and mental health problems or death 3-25-2021 FDA Drug Safety Communication What safety concern is FDA announcing? The U.S. Food and Drug Administration (FDA) is warning that the abuse and misuse of the over- the-counter (OTC) nasal decongestant propylhexedrine can lead to serious harm such as heart and mental health problems. Some of these complications, which include fast or abnormal heart rhythm, high blood pressure, and paranoia, can lead to hospitalization, disability, or death. Reports of individuals abusing and misusing propylhexedrine have increased in recent years. Propylhexedrine is safe and effective when used as directed. What is FDA doing? We are requesting that all manufacturers of OTC propylhexedrine nasal decongestant inhalers consider product design changes that support its safe use. For example, modifying the product to create a physical barrier that would make tampering with the device and abusing the propylhexedrine inside more difficult. In addition, decreasing the amount of medicine the device contains could also reduce the risk of serious side effects if abused or misused. We continue to evaluate this safety issue and will determine if additional FDA actions are needed. What is propylhexedrine and how can it help me? Propylhexedrine is a nasal decongestant that is available OTC in an inhaler. It is used short term to temporarily relieve nasal congestion due to colds, hay fever, or other upper respiratory allergies. It works by reducing swelling and inflammation of the mucous membrane lining of the nose.
    [Show full text]
  • Modified Release
    Product list Modified Release Our product list consist of the pharmaceuticals, pharmaceutical associations and food in the dosages and forms most required by our customers (please check www.osmopharm.com for more details). Our Research and Development competencies are assuring the flexibility in developing new formulations and forms of the products in list as well as new ones. PRODUCTS RELEASE BULK FORM DOSAGE FINAL FORM THERAPEUTICITY A Acetazolamide SR Pellets 500 mg caps Diuretic Alfacalcidol IR Pellets 1 μg caps Vit D supplement Alfuzosin Hydrochloride SR Powder 2.5 mg – 10 mg tabs Prostatic Hypertrophy agent Allopurinol SR Pellets 300 mg caps Antiurolytic Alprazolam SR Pellets 1 mg caps Anxiolytic Ambroxol HCI SR Pellets 75 mg, 120 mg caps Expectorant Ambroxol HCI SR Resinates 75 mg, 120 mg caps / tabs Expectorant Amitriptyline SR Pellets 25 mg, 50 mg, 75 mg caps Antidepressant Aspirin EC, IR Pellets 100 mg caps Anticoagulant Aspirin EC, IR Microcapsules 100 mg caps / tabs Anticoagulant Atenolol IR Pellets 50 mg caps Antihypertensive Azithromycin IR Pellets 250 mg caps Antibiotic B B-complex Benproperine IR Resinates 25 mg, 50 mg caps / tabs Antitussive Betahistine 2HCI SR Pellets 12 mg, 24 mg, 48 mg caps Vasodilator Bromopride* SR Pellets 20 mg caps Antiemetic Brompheniramine maleate SR Pellets 6 mg, 8 mg, 12 mg caps Antihistaminic C Caffeine SR, IR Pellets 25 mg, 50 mg, 300 mg caps CNS Stimulant Carbetapentane citrate SR Pellets 75 mg caps Antitussive Carbinoxamine maleate SR Pellets 4mg, 6 mg caps Antihistaminic Carbinoxamine
    [Show full text]
  • Effectiveness of Bronchodilator and Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease (Copd)
    Journal of Pharmaceutical Science and Application Volume 2, Issue 1, Page 17-22, June 2020 E-ISSN : 2301-7708 EFFECTIVENESS OF BRONCHODILATOR AND CORTICOSTEROID TREATMENT IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) Putu Rika Veryanti1*, Ainun Wulandari1 1Department of Pharmacy, Institut Sains dan Teknologi Nasional, Jakarta, Indonesia Corresponding author email: [email protected] ABSTRACT Background: Chronic Obstructive Pulmonary Disease (COPD) is a chronic airway disease which is characterized by progressive airway obstruction. Bronchodilators and corticosteroids are the first choices of therapy in COPD patients. The goal therapy of COPD patients is to prevent respiratory failure, which can impact on death. But nowadays, the mortality rate due to COPD continues to increase. WHO predicts mortality from COPD in the year 2030 will be ranked third in the world. This high mortality can be caused by the ineffectiveness of therapy given. Objective: The aim of this study is to find out the effectiveness of bronchodilator and corticosteroid treatments in COPD patients. Methods: An observational study conducted retrospectively in the 2018 period at Fatmawati Central General Hospital. The effectiveness of therapy was assessed from the patient's clinical condition, blood gas values (PaO2 & PaCO2) and the average length of stay (AvLOS). Results: COPD was mostly suffered by males (83,33%), and the highest age for COPD was in the range of 45 years and above (90%). Bronchodilator that commonly prescribed were albuterol (30.08%), ipratropium bromide (12.2%), fenoterol hydrobromide (10.57%), terbutaline sulfate (8.13%), theophylline (1.63%) and aminophylline (5.69%), while the corticosteroids were budesonide (17.07%), methylprednisolone (9.76%) and dexamethasone (4.88%).
    [Show full text]
  • Sudafed Decongestant Tablets 12S PIL SNAS 3359 SNAS 3557 14 Mm 29.07.2021 English Rate and Blood Pressure)
    12 mm 12 mm spot = 12 x 2 centered in Distance between cutted the margin of 14 mm line/middel of the spot = 51.6 mm UK_Sudafed Decongestant Tablets 12s_PIL_SNAS 3359_SNAS 3557 14 mm 29.07.2021 English rate and blood pressure). 402059927_r2 N/A Now read this whole leaflet carefully before you use this medicine. Keep the leaflet: you ■ If you have an overactive thyroid Brochure/Leaet/Insert 145 x 250 mm might need it again. gland. 360165B BL-Val de Reuil_France ■ If you have glaucoma (increased CHILD 360165A Multi Packaging Solutions St Pierre 1 What the medicine is for pressure in the eye). 953 Oset Printing Sudafed Decongestant Tablets is a medicine used ■ If you have severe kidney problems. 8169503 PAPER to provide relief from cold, flu and allergy ■ If you are taking beta blockers (used to EMEA_2020_00006767_001 PC-0002778 symptoms such as blocked sinuses, stuffy nose treat high blood pressure). and catarrh. ■ If you are taking, or have taken in the The tablets contain pseudoephedrine last two weeks, drugs for depression ■ This medicine is used to help clear cold, flu hydrochloride, which is a decongestant that known as Monoamine Oxidase and allergy symptoms such as blocked relieves nasal and sinus congestion. Inhibitors (MAOIs) or Reversible Black PANTONE sinuses, stuffy nose and catarrh. This medicine is for use by adults and children Inhibitors of Monoamine Oxidase 3005 C ■ This medicine is for use by adults and (RIMAs). LITHO OFFSET LITHO OFFSET aged 12 years and over. children aged 12 years and over. 145 mm REPRESENTATION: Colours represented with a diagonal line have been modified to aid PDF approval.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases Biological Activities Found in Ammi Visnaga
    Dr. Duke's Phytochemical and Ethnobotanical Databases Biological Activities found in Ammi visnaga Activity Chemical Count 11B-HSD-Inhibitor 2 5-Alpha-Reductase-Inhibitor 3 5-HT-Inhibitor 1 5-Lipoxygenase-Inhibitor 2 ACE-Inhibitor 3 Acetylcholinergic 1 Acidulant 1 Aldehyde-Oxidase-Inhibitor 2 Aldose-Reductase-Inhibitor 11 Allelochemic 5 Allelopathic 3 Allergenic 8 Alpha-Reductase-Inhibitor 1 Analgesic 5 Anemiagenic 1 Anesthetic 3 Anthelmintic 1 Antiacetylcholinesterase 2 Antiacne 3 AntiADD 1 Antiaflatoxin 6 Antiaggregant 5 Antiaging 1 Antiallergenic 1 Antiallergic 5 Antialopecic 2 Antialzheimeran 1 Activity Chemical Count Antianaphylactic 2 Antiandrogenic 3 Antianginal 1 Antiangiogenic 1 Antiapoplectic 1 Antiappetant 1 Antiarteriosclerotic 1 Antiarthritic 1 Antiasthmatic 4 Antiatherogenic 1 Antiatherosclerotic 3 Antibacterial 15 Antibrucellosic 1 Anticancer 6 Anticancer (Kidney) 1 Anticancer (Prostate) 1 Anticapillary-Fragility 1 Anticarcinomic (Breast) 1 Anticariogenic 2 Anticataract 2 Anticlastogen 1 Anticolitic 1 Anticomplementary 1 Anticonvulsant 3 AntiCrohn's 1 AntiCVI 1 Anticystitic 1 2 Activity Chemical Count Antidementia 1 Antidepressant 2 Antidermatitic 3 Antidiabetic 4 Antidiarrheic 1 Antidiuretic 1 Antidote (Camphor) 1 Antidote (Morphine) 1 Antidysenteric 1 Antiedemic 3 Antielastase 2 Antiemetic 1 Antiencephalitic 1 Antierythemic 1 Antiescherichic 2 Antiesherichic 1 Antiestrogenic 2 Antifeedant 7 Antifertility 1 Antifibrinolytic 1 Antifibrosarcomic 1 Antifibrositic 1 Antiflu 1 Antigastric 2 Antigingivitic 3 Antiglaucomic 1 Antigonadotrophic
    [Show full text]
  • Histamine and Antihistamines Sites of Action Conditions Which Cause Release Aron H
    Learning Objectives I Histamine Pharmacological effects Histamine and Antihistamines Sites of action Conditions which cause release Aron H. Lichtman, Ph.D. Diagnostic uses Associate Professor II Antihistamines acting at the H1 and H2 receptor Pharmacology and Toxicology Pharmacological effects Mechanisms of action Therapeutic uses Side effects and drug interactions Be familiar with the existence of the H3 receptor III Be able to describe the main mechanism of action of cromolyn sodium and its clinical uses Histamine Pharmacology First autacoid to be discovered. (Greek: autos=self; Histamine Formation akos=cure) Synthesized in 1907 Synthesized in mammalian tissues by Demonstrated to be a natural constituent of decarboxylation of the amino acid l-histidine mammalian tissues (1927) Involved in inflammatory and anaphylactic reactions. Local application causes swelling redness, and edema, mimicking a mild inflammatory reaction. Large systemic doses leads to profound vascular changes similar to those seen after shock or anaphylactic origin Histamine Stored in complex with: Heparin Chondroitin Sulfate Eosinophilic Chemotactic Factor Neutrophilic Chemotactic Factor Proteases 1 Conditions That Release Histamine 1. Tissue injury: Any physical or chemical agent that injures tissue, skin or mucosa are particularly sensitive to injury and will cause the immediate release of histamine from mast cells. 2. Allergic reactions: exposure of an antigen to a previously sensitized (exposed) subject can immediately trigger allergic reactions. If sensitized by IgE antibodies attached to their surface membranes will degranulate when exposed to the appropriate antigen and release histamine, ATP and other mediators. 3. Drugs and other foreign compounds: morphine, dextran, antimalarial drugs, dyes, antibiotic bases, alkaloids, amides, quaternary ammonium compounds, enzymes (phospholipase C).
    [Show full text]
  • 262 Part 341—Cold, Cough, Al- Lergy, Bronchodilator, And
    Pt. 341 21 CFR Ch. I (4–1–18 Edition) section 502 of the Act relating to mis- treating concurrent symptoms (in either branding and the prohibition in section a single-ingredient or combination drug 301(d) of the Act against the introduc- product). tion or delivery for introduction into 341.72 Labeling of antihistamine drug prod- interstate commerce of unapproved ucts. 341.74 Labeling of antitussive drug prod- new drugs in violation of section 505(a) ucts. of the Act. 341.76 Labeling of bronchodilator drug prod- (c) Warnings. The labeling of the ucts. product contains the following warn- 341.78 Labeling of expectorant drug prod- ings under the heading ‘‘Warnings’’: ucts. (1) ‘‘The recommended dose of this 341.80 Labeling of nasal decongestant drug product contains about as much caf- products. feine as a cup of coffee. Limit the use 341.85 Labeling of permitted combinations of caffeine-containing medications, of active ingredients. foods, or beverages while taking this 341.90 Professional labeling. product because too much caffeine may AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, cause nervousness, irritability, sleep- 360, 371. lessness, and, occasionally, rapid heart EDITORIAL NOTE: Nomenclature changes to beat.’’ part 341 appear at 69 FR 13717, Mar. 24, 2004. (2) ‘‘For occasional use only. Not in- tended for use as a substitute for sleep. Subpart A—General Provisions If fatigue or drowsiness persists or con- tinues to recur, consult a’’ (select one § 341.1 Scope. of the following: ‘‘physician’’ or ‘‘doc- tor’’). (a) An over-the-counter cold, cough, (3) ‘‘Do not give to children under 12 allergy, bronchodilator, or anti- years of age.’’ asthmatic drug product in a form suit- (d) Directions.
    [Show full text]
  • Mucolytic Agents & Decongestants
    Mucolytic Agents & Decongestants Mucolytic agents (Guaifenesin Mucinex® Humibid LA®) are drugs that thin mucus and secretions, so they can drain out of the sinuses more easily. They may be helpful for people suffering from a thick post-nasal drip. Often, they are found in combination preparations with decongestants and/or antihistamines. Most are well tolerated and have few side effects such as headache, rash, or nausea. Topical Nasal Decongestants Topical nasal decongestants (Afrin® or Neosynephrine®) in the form of drops or sprays that are placed in the nose can be very effective in shrinking nasal swelling in minutes. However, these sprays should be used no longer than 2 or 3 consecutive days, for prolonged usage may result in "rebound" swelling of the nose. Rebound swelling (known as "rhinitis medicamentosa") can be extremely difficult to treat because the nose may no longer respond normally to the decongestant spray. We advise that use the brands that contain oxymetazoline in preference to those that have phenylephrine as their active ingredient. The safe use of these medications sometimes can be extended by using the medicine only at bedtime, in alternating nostrils every other night. For example, on the first night only the right nostril receives medicine and on the second night the medicine is placed in your left nostril. By doing this some patients can double the safe use of oxymetazoline. Systemic Decongestants If more prolonged decongestant therapy is required, systemic decongestants may be used. The most well know brand is Sudafed®. It comes in varying strengths and is purchased over the counter. Psuedoephedrine can befound as part of a combination medication with some antihistamines such as Allegra® or Claritin®.
    [Show full text]
  • Desoxyn (Methamphetamine Hydrochloride Tablets, USP)
    ® Desoxyn (methamphetamine hydrochloride tablets, USP) Rx only METHAMPHETAMINE HAS A HIGH POTENTIAL FOR ABUSE. IT SHOULD THUS BE TRIED ONLY IN WEIGHT REDUCTION PROGRAMS FOR PATIENTS IN WHOM ALTERNATIVE THERAPY HAS BEEN INEFFECTIVE. ADMINISTRATION OF METHAMPHETAMINE FOR PROLONGED PERIODS OF TIME IN OBESITY MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING METHAMPHETAMINE FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUG SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY. MISUSE OF METHAMPHETAMINE MAY CAUSE SUDDEN DEATH AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS. DESCRIPTION DESOXYN® (methamphetamine hydrochloride tablets, USP), chemically known as (S)-N,α-dimethylbenzeneethanamine hydrochloride, is a member of the amphetamine group of sympathomimetic amines. It has the following structural formula: DESOXYN tablets contain 5 mg of methamphetamine hydrochloride for oral administration. Inactive Ingredients: Corn starch, lactose, sodium paraminobenzoate, stearic acid and talc. CLINICAL PHARMACOLOGY Methamphetamine is a sympathomimetic amine with CNS stimulant activity. Peripheral actions include elevation of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. Drugs of this class used in obesity are commonly known as “anorectics” or “anorexigenics”. It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions, or metabolic effects, may be involved, for example. Reference ID: 3734642 Adult obese subjects instructed in dietary management and treated with “anorectic” drugs, lose more weight on the average than those treated with placebo and diet, as determined in relatively short-term clinical trials. The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week.
    [Show full text]